These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12714810)

  • 21. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
    Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
    Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):81-6. PubMed ID: 10091030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa.
    Pankey GA; Ashcraft DS
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2959-64. PubMed ID: 15980375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
    Dawis MA; Isenberg HD; France KA; Jenkins SG
    J Antimicrob Chemother; 2003 May; 51(5):1203-11. PubMed ID: 12697632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood.
    Lu DC; Chang SC; Chen YC; Luh KT; Hsieh WC
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):187-91. PubMed ID: 9327247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
    Maesaki S; Yamaguchi T; Sasaki K; Hashikita G; Shibuya S; Watanabe M; Takayama S; Kawakami S; Nagasawa M; Suzuki N; Uchida T; Okabe T; Kobayashi S;
    Jpn J Antibiot; 2006 Feb; 59(1):11-20. PubMed ID: 16673578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM; Johnson DM; Jones RN
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Combination antibacterial effects between aztreonam and eight other antibiotics].
    Nishino T; Obana Y; Kuzui H; Murakami T
    Jpn J Antibiot; 1991 Jan; 44(1):1-8. PubMed ID: 1904106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.
    Bustamante CI; Wharton RC; Wade JC
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1814-5. PubMed ID: 2126693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic activity of amikacin with aztreonam against Pseudomonas aeruginosa and other gram-negative organisms.
    Greenberg RN; Bollinger M; Compton J
    Clin Ther; 1986; 8(3):354-8. PubMed ID: 3087621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative activities of three new antibacterial agents with aztreonam against gram-negative bacilli.
    Kafetzis DA; Legakis NJ
    Chemioterapia; 1987 Jun; 6(2 Suppl):110-2. PubMed ID: 3151330
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [In vitro combined effects of double antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa isolates: comparison among combinations of colistin, arbekacin, aztreonam, rifampicin and piperacillin].
    Nagaoka R; Ikawa K; Onodera M; Koba Y; Hara T; Joichi Y; Yokozaki M; Ohge H; Morikawa N
    Jpn J Antibiot; 2014 Jun; 67(3):167-74. PubMed ID: 25163250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the in vitro susceptibility of veterinary antibiotics with human antibiotics within aminoglycosides, β-lactam and fluoroquinolone antibiotic classes to highly resistant Gram-negative pathogens from human medicine.
    Moore JE; Alcorn M; Rendall JC; Downey DG
    Br J Biomed Sci; 2015; 72(3):146-9. PubMed ID: 26510272
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of the combination of erythromycin with new beta-lactam antibiotics against gram-negative aerobic respiratory pathogens.
    Nakatomi M; Neu HC
    Chemioterapia; 1986 Dec; 5(6):379-84. PubMed ID: 3802298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An in vitro investigation of synergy or antagonism between antimicrobial combinations against isolates from bacterial keratitis.
    Sueke H; Kaye SB; Neal T; Hall A; Tuft S; Parry CM
    Invest Ophthalmol Vis Sci; 2010 Aug; 51(8):4151-5. PubMed ID: 20335613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.
    White RL; Burgess DS; Manduru M; Bosso JA
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1914-8. PubMed ID: 8843303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of gram-negative susceptibility to fluoroquinolones after implementation of a pre-authorization policy for fluoroquinolone use: A decade-long experience.
    Lee RA; Scully MC; Camins BC; Griffin RL; Kunz DF; Moser SA; Hoesley CJ; McCarty TP; Pappas PG
    Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1419-1424. PubMed ID: 30296959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of synergism with combinations of dibromopropamidine isethionate or propamidine isethionate and polymyxin B.
    Richards MR; Xing DK
    J Pharm Pharmacol; 1994 Jul; 46(7):563-6. PubMed ID: 7996383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.